# Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer

> **NCT03310632** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Golden Biotechnology Corporation** · enrollment: 52 (estimated)

## Conditions studied

- Pancreatic Neoplasm

## Interventions

- **DRUG:** Antroquinonol

## Key facts

- **NCT ID:** NCT03310632
- **Lead sponsor:** Golden Biotechnology Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-01
- **Primary completion:** 2023-11-01
- **Final completion:** 2024-12-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03310632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03310632, "Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03310632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*